Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018

Jan. 29, 2019, GUILFORD, Conn. Categories: Financial

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Nov. 30, 2018. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/.

On behalf of the Board of Directors of Bioasis Technologies Inc.

Mark Day, Ph.D., Director and President & Chief Executive Officer